The investment will support advanced human-like cell models for neuroscience, eye, and heart research.
Edinburgh, Scotland, 14 January 2026 – Axol Bioscience Ltd. (Axol), a leading company in induced pluripotent stem cell (iPSC) technologies for drug discovery and disease research, has announced that it has raised $2.8 million (£2.1 million) in new funding. The investment was led by US life sciences specialist BroadOak Capital Partners, with participation from Axol’s founding investor, the Roslin Foundation.
According to Axol, this funding will help accelerate the company’s next stage of growth by expanding its US operations and strengthening its commercial presence in the American market. The investment will also support the development of improved disease models in neuroscience, ophthalmology, and cardiovascular research. In addition, Axol plans to scale up cell manufacturing at its base in the Roslin Innovation Centre, located near Edinburgh, to meet rising global demand for more human-relevant lab models.
Axol Bioscience is known for producing high-quality iPSC-derived cells, research reagents, and specialized services used by pharmaceutical companies, biotech firms, contract research organizations (CROs), and academic institutions worldwide. The company has built a strong reputation for creating physiologically relevant human cell models that help researchers better understand diseases and test new treatments in the lab.
In recent years, Axol has strengthened its position in neurodegenerative disease research by providing advanced iPSC-derived models for conditions such as Huntington’s disease and sporadic amyotrophic lateral sclerosis (ALS/MND). These areas remain major challenges in modern medicine, and many researchers continue to look for improved tools that can mirror human biology more accurately than older lab methods.
Axol’s leadership said the investment comes at a time of strong performance for the business. Chief Financial Officer Oliver Richardson shared that the company achieved 45% revenue growth in 2025, following 36% growth in 2024. He added that this funding will help Axol expand manufacturing capacity at its Edinburgh site and ensure it can keep up with increasing global demand.
BroadOak Capital Partners also highlighted its confidence in Axol’s market position. Daniel Friedman, Managing Director at BroadOak, stated that Axol is well placed in the industry as the life sciences field continues to move toward cell-based research models that better reflect real human conditions.
The funding follows a period of steady momentum for Axol, including double-digit revenue growth, continuous expansion of its iPSC disease model portfolio, and ongoing investment in manufacturing and quality systems. Over the past year, the company has also strengthened partnerships with global pharmaceutical organizations and increased its reach in the US market, supporting its long-term goal of becoming a leading supplier of human-relevant in vitro disease models.
